INDAZOLYLISOXAZOLE DERIVATIVES FOR TREATING DISEASES SUCH AS MALIGNANT GROWTH Russian patent published in 2025 - IPC C07D231/56 C07D413/04 C07D413/14 C07D417/14 C07D471/10 C07D487/04 C07D491/107 A61K31/416 A61P35/00 

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula I

in which R¹ means Hal, CF₃, OA, Het¹, COOR³ or CON(R³)₂, R² means H, Hal or CN, R³ means H or A, X denotes phenylene, pyridine diyl, 1,3-thiazole diyl, each of which is unsubstituted or monosubstituted with Hal and/or A, Y is absent or CO, O[C(R³)₂]_n, NR³CO, CONR³, CONR³[C(R³)₂]_n, CONHCH₂C(CH₃)₂, SO₂, SO₂N(R³), -N= or S(=O,=NR³), Z means H, A, OA, [C(R³)₂]_nHet² or N=S(=O)A₂, A denotes a straight or branched alkyl containing 1–10 C atoms, in which one or two CH- and/or CH₂-groups, which are not located next to each other, can be replaced with O atoms and where 1–7 H atoms can be replaced with R⁵, or means (CH₂)_nCyc, Cyc denotes a cyclic alkyl containing 3–7 C atoms, R⁵ means OH, SO₂A or N(R³)₂, Het¹ denotes pyrazolyl, which can be monosubstituted by A, Het² denotes 4–7-membered monocyclic aromatic, unsaturated or saturated heterocycle containing from 1 to 3 N, O and/or S atoms, which can be unsubstituted or mono-, di- or trisubstituted by A, Hal, CN, OR³, [C(R³)₂]_nN(R³)₂, [C(R³)₂]_nSO₂A, [C(R³)₂]_nNR³SO₂A, Het³, =NR³ and/or =O, or denotes 7–10-membered bicyclic aromatic, unsaturated or saturated heterocycle containing from 1 to 3 atoms of N, O and/or S, which can be unsubstituted or mono-, di- or trisubstituted by A, Hal, Het³ and/or =O, Het³ denotes 4–6-membered monocyclic aromatic, unsaturated or saturated heterocycle containing from 1 to 3 N, O and/or S atoms, which can be unsubstituted or mono- or disubstituted by A, Hal, OR³, oxetanyl and/or =O, or denotes 7-membered bicyclic aromatic, unsaturated or saturated heterocycle containing from 1 to 2 N and/or O atoms, Hal denotes F, Cl, Br or I, n denotes 0, 1, 2 or 3, and pharmaceutically acceptable salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, provided that the compound of formula I does not include 6-chloro-3-[5-(3-methoxyphenyl)-3-isoxazolyl]-1H-indazole and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof , including mixtures thereof in all ratios, as well as to methods of producing, drugs for inhibiting c-KIT kinase and for treating and/or preventing malignant growth, where the malignant neoplasm is a gastrointestinal malignant neoplasm.

EFFECT: obtaining novel compounds which can be used as c-KIT kinase inhibitors and for treating and/or preventing malignant growth, where the malignant neoplasm is a gastrointestinal malignant neoplasm.

12 cl, 2 tbl, 22 ex